According to the market research report released by Technavio, the global pulmonary arterial hypertension (PAH) drugs market is expected to accelerate at a CAGR of more than 3% during the forecast period. New-disease modifying therapies is one of the key factors triggering the growth of the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926006051/en/
According to the market research report released by Technavio, the global pulmonary arterial hypertension (PAH) drugs market is expected to accelerate at a CAGR of more than 3% until 2021. (Graphic: Business Wire)
This research report titled 'Global Pulmonary Arterial Hypertension Drugs Market 2017-2021' provides an in-depth analysis of the market in terms of revenue and emerging market trends. It also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
The market research analysis categorizes the global PAH drugs market into the following route of administration:
- Inhalation
- Injectables
- Oral administration
In 2016, the oral administration segment led the PAH drugs market. Oral administration comprises of tablets and suspensions and tablets can be branched as film-coated tablets and extended-release tablets. Since the study of widespread animal and human efficacy and safety is not required in these formulations, the market segment is likely to witness growth in the coming years.
Global pulmonary arterial hypertension drugs market: Top emerging trend
The increased focus on combination therapies is an emerging trend in this market space. The PAH treatment is shifting toward the use of combination therapies that employ two or more drugs. A combination therapy with separate agents or a fixed dose of combination pill offers the maximum potential to lower blood pressure. The treatment is also aimed at targeting various disease mechanisms that may result in better outcome. These outcomes include improvement in pulmonary hemodynamics, patient's survival, and exercise capacity.
Looking for more information on this market? Request a free sample report
Technavio's sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Technavio's report provides expert market research on the following topics:
Executive Report
- Market Outline
- Global PAH Drugs Market Overview
Market Insights
- Market Sizing and Forecasts
- Market Growth
- Market Drivers and Challenges
- Key Emerging Trends
Market Segmentation Analysis
- Regional comparison (APAC, Americas, and EMEA)
- Key leading countries
- Market segmentation by route of administration (inhalation, injectables, and oral administration)
- Market segmentation by mechanism of action (ERAs, prostacyclin analogs, PDE inhibitors, and sGC stimulators)
Vendor Landscape
- Vendor classification
- Market positioning of vendors
- Competitive scenario
- Analysis of top vendors (Actelion Pharmaceuticals, DAIICHI SANKYO, GlaxoSmithKline, Novartis, and United Therapeutics)
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180926006051/en/
Contacts:
Technavio Research
Jesse Maida
Media Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com